Snapshot from Jun 09, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Gossamer Bio faces securities lawsuit
Regulatory securities lawsuit

Gossamer Bio faces securities lawsuit

Analysis based on 12 articles · First reported May 18, 2026 · Last updated May 29, 2026

Sentiment
-70
Attention
4
Articles
12
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is negatively impacted by the significant decline in the stock price of Gossamer Bio, which plummeted over 80% in a single trading day. This event highlights the risks associated with pharmaceutical trials and potential liabilities for publicly traded companies due to alleged misleading statements, affecting investor confidence in the biotechnology sector.

Biotechnology Legal Services
Event Summary

Faruqi & Faruqi, a national securities law firm, is investigating potential claims against Gossamer Bio, Inc. and reminding investors of the June 1, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Gossamer Bio and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose issues with the study design for its Phase 3 PROSERA study, specifically regarding the placebo response at Latin American testing sites. This follows Gossamer Bio's announcement on February 23, 2026, of adverse topline results from the PROSERA study, which failed to meet its primary endpoint. The company's stock price subsequently dropped by over 80% from $2.13 to $0.42 per share.

Key Actions
100 Gossamer Bio made false statements
90 Faruqi & Faruqi investigating claims Gossamer Bio
80 Faruqi & Faruqi reminded investors
70 Gossamer Bio attributed outcome
Entities Involved
stock
Gossamer Bio
Gossamer Bio is the defendant in a federal securities class action lawsuit due to alleged misleading statements regarding its Phase 3 PROSERA study, which led to a significant drop in its stock price.
Importance 100 Sentiment -80
priv
Faruqi & Faruqi
Faruqi & Faruqi is a national securities law firm investigating potential claims against Gossamer Bio and reminding investors of the deadline to seek lead plaintiff status in the class action lawsuit.
Importance 80 Sentiment 50
per
James Wilson
James Wilson is a Securities Litigation Partner at Faruqi & Faruqi, encouraging investors who suffered losses in Gossamer Bio to contact him to discuss their legal options.
Importance 60 Sentiment 30
index
Nasdaq-100
Nasdaq-100 is the stock exchange where Gossamer Bio's shares are traded, and where its stock price plummeted following the adverse study results.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.